Pharmaceutical group Clinigen undergoes ‘strategically transformational year’
STAFFORDSHIRE pharmaceutical group Clinigen has undergone a strategically transformational year, its chief executive has said.
Peter George, delivering his report to the group’s AGM, said during the year, Burton-upon-Trent-based Clinigen had doubled the size of the business, strengthened its global capabilities, become the global market leader in the ethical supply of unlicensed medicines and continued the revitalisation of its speciality products portfolio.
He said with the acquisition of Idis, the group had extended its unique, synergistic business model and created a better balanced portfolio of businesses.
Clinigen is now the market leader in the $5+ billion unlicensed medicine supply sector and the $2 billion clinical trial supply market. The proposed acquisition of Link, due to complete shortly, is also likely to substantially broaden the group’s international distribution footprint across the AAA region – Asia, Africa and Australasia, he added.
The group said in its full year results in September that all of its newer specialty pharma assets – Cardioxane, Savene and Ethyol – were progressing to plan. The lifting of the EMA Article 31 referral for Cardioxane also remains on track, it added.
Having completed the CFO handover period, Robin Sibson will step down from the role of CFO after the AGM and Martin Abell will then assume that role with immediate effect.
Sibson will continue to work with the group in his new role as a Non-Executive Director of the business.
Looking ahead, the group said: “Clinigen’s strong financial performance demonstrates its strengthened international position in growing markets. The group is on track in advancing its underlying philosophy of getting the right drug to the right patient at the right time, regardless of where they are in the world.”
